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OBJECTIVES The purpose of this study was to prospectively examine the role of clinical, laboratory,
echocardiographic, and electrophysiological variables as predictors of appropriate initial
implantable cardioverter-defibrillator (ICD) therapy for ventricular tachycardia (VT) or
ventricular fibrillation (VF) or death in the Multicenter Automatic Defibrillator Implantation
Trial II (MADIT-II) population.
BACKGROUND There is limited information regarding the determinants of appropriate ICD therapy in
patients with reduced ventricular function after a myocardial infarction.
METHODS We used secondary analysis in one arm of a multicenter randomized clinical trial in patients
with a previous myocardial infarction and reduced left ventricular function.
RESULTS We analyzed baseline and follow-up data on 719 patients enrolled in the ICD arm of the
MADIT-II study. Appropriate ICD therapy was observed in 169 subjects. Clinical, laboratory,
echocardiographic, and electrophysiological variables, along with measures of clinical instability
such as interim hospitalization for congestive heart failure (IH-CHF) and interim hospitalization
for coronary events (IH-CE), were examined with proportional hazards models and Kaplan-
Meier time-to-event curves before and after first interim hospitalization. Interim hospitalization-
CHF, IH-CE, no beta-blockers, digitalis use, blood urea nitrogen (BUN)25, body mass index
(BMI) 30 kg/m2, and New York Heart Association functional class II were associated with
increased risk for appropriate ICD therapy for VT, VF, or death. In a multivariate (stepwise
selection) analysis, IH-CHF was associated with an increased risk for the end point of either VT
or VF (hazard ratio [HR] 2.52, 95% confidence interval [CI] 1.69 to 3.74, p 0.001) and for the
combined end point of VT, VF, or death (HR 2.97, 95% CI 2.15 to 4.09, p  0.001). Interim
hospitalization-CE was associated with an increased risk for VT, VF, or death (HR 1.66, 95% CI
1.09 to 2.52, p  0.02).
CONCLUSIONS These results provide important mechanistic information, suggesting that worsening clinical
condition and cardiac instability, as reflected by an IH-CHF or IH-CE, are subsequently
associated with a significant increase in the risk for appropriate ICD therapy (for VT/VF)
and death. (J Am Coll Cardiol 2005;46:1712–20) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.088Cardiology Foundation
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dheMulticenter Automatic Defibrillator Implantation Trial II
MADIT-II) has shown that patients with a previous myo-
ardial infarction (MI) and advanced left ventricular dysfunc-
See page 1727
ion (left ventricular ejection fraction [LVEF] 30%) benefit
rom prophylactic implantation of a defibrillator (1). The
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ccepted May 10, 2005.esults of this study have expanded the previously recom-
ended use of implantable cardioverter-defibrillator (ICD)
herapy, resulting in cost implications on the health care
ystem. Calculations have suggested that this increase in the
umber of patients eligible for ICD implantation will result
n many patients receiving ICDs that are never used (2).
his, in turn, has caused much debate concerning the
linical acceptance of the MADIT-II results. Also, recently
pdated American College of Cardiology/American Heart
ssociation/Heart Rhythm Society guidelines have ex-
ressed the need for further risk stratification of the
ADIT-II population to better identify patients likely to
enefit from ICD therapy (3). The present study sought to
etermine the role of interim measures of clinical instability
long with baseline clinical, laboratory, echocardiographic,
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November 1, 2005:1712–20 Factors Influencing Appropriate ICD Firingnd electrophysiological variables in predicting appropriate
CD therapy for ventricular tachyarrhythmias and death in
he MADIT-II patient population. This might improve the
ost-ICD implantation care and also enable better risk
tratification in this patient group.
ETHODS
tudy subjects. The MADIT-II was a prospective multi-
enter trial that enrolled subjects from 76 hospital centers. A
escription of the study design and protocol has been
reviously published (1,4). Patients 21 years of age and of
ither gender were eligible for the study if they had had an
I one month or more before entry, as documented by the
nding of an abnormal Q-wave on electrocardiography,
levated cardiac enzymes during hospitalization for a sus-
ected MI, a fixed defect on thallium scanning, or localized
kinesis on ventriculography with evidence of obstructive
oronary artery disease on angiography, and an ejection
raction of 0.30 within three months before entry as
uggested by angiography, radionuclide scanning, or echo-
ardiography (1,4).
Definitions of all clinical variables were outlined before
he start of the MADIT-II. Subjects underwent a detailed
linical evaluation and a spectrum of invasive and non-
nvasive electrophysiological risk-stratification procedures.
aseline device settings were uniform among all subjects.
ollow-up. All data of baseline characteristics, including
he results of the invasive and non-invasive cardiac evalua-
ion, were prospectively collected in the MADIT-II study
opulation. Patients were followed up in each center, and
ata concerning all ICD therapy were obtained at the time
f device interrogation and retrieval of stored electrograms.
he end point review committee received detailed reports of
he events, reports from the emergency room, hospital
ecords, and outpatient visits. Careful records were obtained
f the time to death after symptom onset, site of death, and
schemic symptoms. Records of interim hospitalization for
eart failure (IH-CHF) or interim hospitalization for cor-
Abbreviations and Acronyms
BMI  body mass index
BUN  blood urea nitrogen
CE  coronary events
CHF  congestive heart failure
CI  confidence interval
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
IH  interim hospitalization
LVEF  left ventricular ejection fraction
MADIT-II  Multicenter Automatic Defibrillator
Implantation Trial II
MI  myocardial infarction
NYHA  New York Heart Association
VF  ventricular fibrillation
VT  ventricular tachycardianary events (IH-CE) were kept by the caring physicians Tnd used as post-implantation surrogates of clinical
nstability.
tatistical analysis. Baseline clinical characteristics were
ompared between two groups with and without ICD therapy
r those with and without experience of interim hospitaliza-
ions by the chi-square test. Multivariate Cox proportional
azards regression analysis was used to identify and evaluate
isk factors associated with first occurrence of appropriate
CD therapy. These risk factors comprised measured base-
ine characteristics of patients and time-dependent factors
uring follow-up, such as “time of first” IH-CHF or
H-CE (angina or MI). Two combined end points were
sed, namely, the first appropriate therapy for ventricular
achycardia (VT) or for ventricular fibrillation (VF), here-
fter VT/VF, and VT/VF/death; the former is of primary
nterest, but results of the analyses are somewhat biased by
he necessity of censoring patients at death, whereas the
atter provides a fully valid comparison analysis. The final
egression analysis was built in three steps: 1) stepwise
election from all available variables of interest, but omitting
rug usage at baseline, for each end point separately (with p
0.1 for retention); 2) addition to the model of each
ategory of drugs used at baseline, one at a time, and
etained if providing a significant effect; and 3) re-fitting
ach end point model with risk factors retained in at least
ne of the two end point models. Upon finding interim
ospitalization variables as significant risk factors, we re-
tted the models, allowing for different effects of these
ospitalizations in patients initially in New York Heart
ssociation (NYHA) functional classes I to II and classes
II to IV and tested for significant interaction. Freedom
rom arrhythmia (ICD therapy) was evaluated by the
aplan-Meier method. Before and after interim hospital-
zation of the follow-up period shows the probability of an
nd-point event. For these, the follow-up of a patient is
oved from before to after, and initialized to zero, upon
ccurrence of the hospitalization. No formal statistical
esting comparing before and after curves is feasible, owing
o overlapping groups of patients. The p values are two-
ided and considered statistically significant when 0.05.
ESULTS
aseline characteristics. We analyzed baseline and follow-up
ata on 719 of 742 patients in the ICD arm of the
ADIT-II study, having excluded 22 patients who did not
eceive an ICD and one patient who dropped out shortly
fter the implantation. Patient characteristics for the two
roups (i.e., with and without ICD therapy) are listed in
able 1. The subjects receiving ICD therapy had a higher
ody mass index (BMI) and worse functional NYHA
unctional class at baseline and a lower ejection fraction.
hese patients were more likely to have had an IH-CHF or
H-CE. There were no significant differences in age, gender
istribution, blood pressure, or other cardiac risk factors.
here were no differences between the two groups with
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Factors Influencing Appropriate ICD Firing November 1, 2005:1712–20espect to electrocardiographic, invasive and non-invasive
lectrophysiological tests, or ejection fraction. Of note,
eta-blocker and angiotensin-converting enzyme (ACE)
nhibitor use was similar in both groups. Electrocardio-
raphic findings of a wide QRS duration, left bundle branch
lock or right bundle branch block, and atrial fibrillation
ere not associated with increased ICD therapy. There was
higher incidence of sudden (7.1% vs. 2.4%) and non-
udden cardiac (10.1% vs. 4.8%) death in the patient
opulation receiving appropriate ICD therapy (for VT/VF)
ersus those free of ICD intervention.
eterminants of ICD therapy and death. During the
7.2-month average follow-up, appropriate ICD therapy
as observed in 169 (24%) of 719 subjects. The index
rrhythmia was VF in 30 patients (18%) and VT in 139
atients (82%). Of the patients with ICD therapy for
able 1. Clinical Characteristics of ICD Patients With and
ithout ICD Therapy
Variables
No ICD
Therapy
(n  550)*
Appropriate
ICD Therapy
(n  169)* p Value
linical examination
Female 16.5 12.4 0.197
Age 65 yrs 52.7 55.0 0.600
Heart rate 80 (beats/min) 29.5 30.5 0.797
BMI 30 kg/m2 28.0 37.3 0.022
Diastolic BP 80 mm Hg 26.7 30.2 0.380
Systolic BP 130 mm Hg 34.5 37.9 0.429
linical history
Hypertension (on Rx) 53.7 52.7 0.805
Diabetes 34.2 32.5 0.694
CHF (NYHA functional
class II)
28.3 36.9 0.034
IH-CHF 18.9 37.9 0.001
IH-CE 12.0 18.9 0.022
S/P CABG 58.7 46.8 0.658
edications
Beta-blockers 65.6 59.2 0.125
ACE inhibitor 77.6 77.5 0.974
Diuretic 72.0 78.1 0.116
Digitalis 58.2 65.1 0.109
Statin 65.5 59.2 0.137
aboratory tests
BUN 25 mg/dl 27.2 33.5 0.113
Creatinine 1.4 mg/dl 26.4 23.1 0.385
CG
QRS 0.12 38.0 42.0 0.348
Left bundle branch block 18.5 20.9 0.506
Right bundle branch block 8.9 9.5 0.808
Atrial fibrillation 8.4 9.5 0.674
chocardiography
LVEF 25% 45.6 53.8 0.062
lectrophysiological study
Inducible 34.3 39.7 0.240
All values expressed as percentages with the indicated variable.
ACE  angiotensin-converting enzyme; BMI  body mass index; BP  blood
ressure; BUN  blood urea nitrogen; CE  coronary events (angina or myocardial
nfarction); CHF  congestive heart failure; ECG  electrocardiogram; ICD 
mplantable cardioverter-defibrillator; IH  interim hospitalization; LVEF  left
entricular ejection fraction; NYHA  New York Heart Association; S/P CABG 
tatus post coronary artery bypass graft surgery.T/VF, 37% were in NYHA functional class II. The hean duration of the VT or VF episodes triggering device
herapy from the onset until termination of the arrhythmia
as 20.1 and 27.3 s for VT and VF, respectively. Interim
ospitalization-CHF, IH-CE, no beta-blockers, digitalis
se, male gender, blood urea nitrogen (BUN) 25 mg/dl,
MI 30 kg/m2, and NYHA functional class II were
ssociated with increased risk for appropriate ICD therapy
or VT or VF and death. Multivariate stepwise regression
nalysis with the Cox proportional hazards model identified
he time-dependent risk factor IH-CHF as associated with
two- to three-fold increased risk for ICD therapy for VT
r VF, with a hazard ratio (HR) of 2.52 (95% confidence
nterval [CI] 1.69 to 3.74, p  0.001) and for a combined
nd point of VT, VF, and death, HR 2.97 (95% CI 2.15 to
.09, p  0.001). An IH-CE was associated with an
ncreased risk for VT, VF, and death, HR 1.66 (95% CI
.09 to 2.52, p  0.02). When stratified by NYHA
unctional class, the risk associated with IH-CHF and
H-CE for VT/VF and death was higher in patients with
YHA class 2, compared with those with a higher
YHA class (Table 2). An IH-CE did not significantly
ncrease the risk for VT/VF alone and was not associated
ith risk for VT/VF and death in the sicker patients with
YHA functional class III and IV function.
The clinical profile of patients with IH-CHF was mark-
dly different from those without IH-CHF (Table 3).
ubjects with IH-CHF were more likely to be women,
iabetics, have an elevated BUN and creatinine, NHYA
unctional class 2, have atrial fibrillation, lower ejection
ractions, lower use of beta blockers and higher use of
igitalis, heart rate 80 beats/min, and QRS duration of
120 ms (Table 3). From these clinical characteristics, only
worse functional class (NYHA II), no beta-blockers,
igitalis use, BUN 25 mg/dl, and BMI 30 kg/m2 were
ssociated with ICD therapy in the multivariate model
Table 2). Patients with IH-CE were noted to be hyper-
ensive and to have an elevated serum BUN and creatinine,
s compared with those without IH-CE.
Kaplan-Meier curves show an increased probability for
ppropriate ICD therapy after (post-CHF) compared with
efore (pre-CHF) hospitalization for CHF. The pre-CHF
urve refers to follow-up time of patients before IH-CHF,
nd post-CHF refers to follow-up time after hospitalization
or CHF. These results were consistent for combined end
oints: VT and VF, as well as a combined end point of VT,
F, and death (Figs. 1A and 1B). Similar trends were
bserved among patients with IH-CE for the combined end
oint of VT/VF and death but not for VT/VF alone (Figs.
A and 2B).
Separate Kaplan-Meier graphs were constructed for IH-
HF, sub-stratified by NYHA functional class. In the
ower NYHA classes (I and II), there was a significantly
igher probability of ICD therapy for VT/VF for those who
ad IH-CHF (Fig. 3A); however, hospitalization for CHF
ad little impact on the probability of appropriate ICD
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ional classes III and IV; Fig. 3B).
ISCUSSION
his study addresses the frequently asked question of
hether there are any clinical determinants of ICD therapy
nd death within the population of patients with previous
Is and advanced left ventricular dysfunction. Our results
how that 1) among a comprehensive list of baseline clinical,
chocardiographic, and electrophysiological variables (used
ithin this study), more symptomatic patients (NYHA
unctional class II) with BUN 25 mg/dl, higher BMI,
nd less beta-blocker use and increased digitalis use at
aseline are at a greater risk for a first time appropriate ICD
herapy for VT/VF and/or death; 2) IH-CHF exacerbation
nd IH-CE are strongly associated with an increased risk
or ICD therapy and death; and 3) increased ICD therapy
as observed in less sick patients (NYHA functional classes
and II) who had worsening of their clinical status. To our
nowledge, this is the first study to highlight the importance
f interim measures of clinical instability and their power to
dentify a subgroup (within this already high-risk popula-
ion) at greater risk for ICD therapy and death.
eterminants of ICD therapy and death. Among the
everal clinical variables assessed for their role as predictors
f ICD therapy or death in the MADIT-II patient pop-
lation, interim measures of hospitalization stood out as
ignificant determinants of appropriate ICD therapy. Pre-
ious reports have indicated that QRS duration is associated
ith overall cardiac mortality (5,6) and sudden death (7). In
Table 2. Multivariate Proportional-Hazards M
Cardiac-Related Hospitalizations as Risk Facto
Risk Factor
VT/VF En
Hazard Ratio (95%
IH-CHF* 2.52 (1.69–3.74)
IH-CHF in NYHA
functional class I–II
3.20 (1.97–5.19)
IH-CHF in NYHA
functional class III–IV
1.90 (1.02–3.55)
IH-CE* 1.43 (0.84–2.42)
IH-CE in NYHA
functional class I–II
1.76 (0.96–3.22)
IH-CE in NYHA
functional class III–IV
1.02 (0.38–2.75)
NYHA functional class II 1.32 (0.95–1.83)
BUN 25 mg/dl 1.29 (0.93–1.79)
Male 1.71 (1.07–2.75)
BMI 30 kg/m2 1.45 (1.05–2.00)
Digitalis at baseline 1.14 (0.83–1.58)
No beta-blockers at baseline 1.18 (0.86–1.62)
*Time-dependent risk factors: IH-CHF; IH-CE. The analys
classes I to II and classes III to IV, with results shown in the in
ratios had p values of 0.19 and 0.07 for the respective end po
CI confidence interval; VF ICD therapy for ventricul
abbreviations as in Table 1.ur study, there was no association of ICD therapy with LRS width, when the latter was examined as either a
ontinuous or dichotomized (120 ms) variable.
Previous reports have shown that an elevated heart rate at
aseline is associated with future occurrences of ventricular
achyarrhythmias (8) and that beta-blocker therapy is asso-
iated with a reduced recurrence of VT/VF and ICD shocks
9,10). In the current analysis, an inverse association be-
ween beta-blocker use and ICD therapy was observed,
hereas an elevated heart rate was not predictive of ICD
herapy and/or death. The absence of this association
etween heart rate and ICD therapy could be explained by
he high use of beta-blockade in our study and slight
ifferences in the mean heart rate between the two groups.
Severity of left ventricular dysfunction has been consis-
ently shown to be a predictor of overall mortality and
udden death (11–13). In this study, it was observed that
urther sub-stratification of LVEF in this pre-selected
igh-risk group (LVEF 30% and coronary artery disease)
as not associated with an increased risk for VT, VF, or
eath. Our findings are dissimilar to the results of other
tudies, such as Levine et al. (14), who found that an
jection fraction 25% was predictive of cardiac events.
his difference is most likely a consequence of the under-
ying differences in the patient population and comparative
roups being evaluated as well as treatment strategies
vailable at that time. A recent retrospective analysis of the
anadian Implantable Defibrillator Study (15) showed that
atients with LVEF 35% and aged 70 years were more
ikely to benefit from an ICD. Our results found no
ssociation with age and further sub-stratification of the
for Time to ICD Therapy, Including Interim
nt VT/VF/Death End Point
p Value Hazard Ratio (95% CI) p Value
0.001 2.97 (2.15–4.09) 0.001
0.001 3.93 (2.65–5.83) 0.001
0.04 2.22 (1.37–3.62) 0.001
0.19 1.66 (1.09–2.52) 0.02
0.07 2.36 (1.48–3.77) 0.001
0.97 0.87 (0.38–1.99) 0.74
0.10 1.41 (1.06–1.86) 0.02
0.13 1.56 (1.18–2.05) 0.002
0.03 1.54 (1.04–2.28) 0.03
0.02 1.21 (0.90–1.61) 0.20
0.42 1.35 (1.01–1.80) 0.04
0.31 1.33 (1.01–1.75) 0.04
repeated, allowing different IH effects in NYHA functional
rows. Tests for differences between the class-specific hazard
r IH-CHF and 0.35 and 0.04 correspondingly for IH-CE.
llation; VT ICD therapy for ventricular tachycardia; otherodel
rs
d Poi
CI)
is was
dented
ints fo
ar fibriVEF 25%. The presence of an association between
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Factors Influencing Appropriate ICD Firing November 1, 2005:1712–20YHA (functional class II) and ICD therapy in the
ultivariate model was similar to a recent report from
hang et al. (16); however, the present study provides more
han a single baseline gauge of CHF severity (i.e., NYHA
unctional class) and incorporates a measure of change in
linical state through IH-CHF or angina, unlike the previous
eport (16). Of note, other electrophysiological measures (in-
asive and non-invasive) were not noted to be determinants of
CD therapy in the MADIT-II population (17,18).
HF, CE, and ICD therapy. Congestive heart failure
econdary to coronary artery disease is associated with a
igher mortality and sudden cardiac death rate when com-
ared with other etiologies (1,19–21). Whereas the clinical
utcome of patients with coronary artery disease and left
entricular dysfunction has improved with the use of beta-
lockers and ACE inhibitors, sudden cardiac death contin-
es to take its toll and remains a significant problem in this
opulation. Although functional class correlates poorly with
VEF (12,22), both LVEF and cardiac functional status
ave been shown to be independent risk factors for arrhyth-
ic death and device discharges (13,16). In our study, the
able 3. Comparison of Clinical Characteristics of Patients With
IH-CHF) or Coronary Events (IH-CE)
Variables
No IH-CHF
(n  550)*
IH-
(n 
linical examination
Female 13.8 2
Age 65 yrs 51.3 6
Heart rate 80 beats/min 26.5 4
BMI 30 kg/m2 30.2 2
Diastolic BP 80 mm Hg 29.5 2
Systolic BP 130 mm Hg 36.7 3
linical history
Hypertension (on Rx) 52.5 5
Diabetes 30.2 4
CHF (NYHA functional class II) 26.7 4
IH-CE 9.8 2
IH-CHF 0 10
S/P CABG 58.4 5
edications
Beta-blockers 67.3 5
ACE inhibitor 78.2 7
Diuretic 68.5 8
Digitalis 56.9 6
Statins 67.1 5
aboratory tests
BUN 25 mg/dl 24.4 4
Creatinine 1.4 mg/dl 22.2 3
CG
QRS 0.12 36.3 4
Left bundle branch block 17.4 2
Right bundle branch block 8.8
Atrial fibrillation 6.8 1
chocardiography
LVEF 25% 44.0 5
lectrophysiologic study
Inducible 36.2 3
All values expressed as percentages with the indicated variable.
Abbreviations as in Table 1.esults of the multivariate Cox regression analysis of baseline ilinical variables suggests that in a pre-selected high-risk
opulation with LVEF 30%, further sub-stratifying the
opulation by ejection fraction (25% vs. 25% to 30%) did
ot add to the predictive value for ICD therapy. Although
n the MADIT-II population, a significant association was
oted between NYHA functional class II and ICD
herapy, there is relatively reduced ICD therapy after
H-CHF in this group of patients. This suggests that this
ubset of patients is already so sick that other variables (i.e.,
orsening of clinical status) do not have additional predic-
ive value as a determinant of ICD therapy. This also
upports the evidence that in sicker heart failure subjects,
he cause of death is more likely owing to pump failure,
udden bradyarrhythmias, or electromechanical dissociation
12). Our results highlight the increased incidence of ICD
herapy in less sick patients (NYHA functional class II).
his is supported by recent data from the Sudden Cardiac
eath in Heart Failure Trial, where patients with NYHA
unctional class II (as opposed to NYHA functional class
II) seemed to benefit more from ICDs (23). New data from
he MADIT-II study have also shown that patients receiv-
Without Interim Hospitalization for Heart Failure
* p Value
No IH-CE
(n  621)*
IH-CE
(n  98)* p Value
0.02 15.6 15.3 0.937
0.04 53.6 51.0 0.631
0.001 29.7 29.9 0.972
0.917 29.1 36.7 0.128
0.04 27.5 27.6 0.998
0.171 35.1 36.7 0.754
0.280 51.9 63.3 0.037
0.001 33.5 35.7 0.666
0.001 29.6 34.7 0.312
0.001 0 100
20.0 44.9 0.001
0.886 58.1 59.2 0.844
0.001 64.4 62.2 0.678
0.482 77.5 78.6 0.806
0.001 72.5 79.6 0.138
0.005 58.8 66.3 0.157
0.001 64.4 61.2 0.541
0.001 27.1 38.8 0.017
0.001 23.9 36.7 0.007
0.013 39.3 36.7 0.631
0.06 19.6 15.7 0.389
0.701 9.5 5.6 0.230
0.001 8.3 11.2 0.334
0.001 46.4 55.1 0.1208
0.600 35.5 35.9 0.950and
CHF
168)
1.4
0.1
0.4
9.8
1.4
1.0
7.2
5.8
1.7
6.2
0
7.7
3.6
5.6
9.3
9.0
3.6
2.9
6.5
7.0
4.2
9.8
4.9
8.9
3.8ng ICD therapy are at higher risk for developing heart
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eed for increased clinical vigilance and continued medical
are after ICD therapy (24).
Myocardial ischemia and its association with ventricular
rrhythmias are well described. Recent data have shown
ngina to be a predictor of new malignant arrhythmias in
atients with coronary artery disease (25). There are, how-
ver, scant prospective data showing this mechanistic rela-
ionship between angina and ICD therapy in patients with
oronary artery disease. Our data demonstrate that angina
nd coronary events requiring hospitalization are predictive
f ICD therapy and death in this group of patients. By
ogical extension, IH-CHF and IH-CE are also likely to
igure 1. Kaplan-Meier curves for the probability of receiving appropriat
ospitalization for congestive heart failure (CHF) (Post CHF) compared w
he curves for combined ventricular tachycardia (VT) and ventricular fibri
espectively.e predictive of subsequent sudden cardiac death in ratients who meet MADIT-II criteria, but do not have
efibrillators.
linical implications. The ICD has become the therapy of
rst choice to prevent sudden cardiac death in high-risk
atients. Our study also supports the well-understood clin-
cal notion that continued clinical vigilance toward prevent-
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ecrease the risk of sudden cardiac death and ICD therapy
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These findings are pertinent to the entire MADIT-II
opulation, independent of NYHA functional class. These
esults are corroborated by recent studies that show that
reventing progression of heart failure with cardiac resynchro-
ization therapy reduces the incidence of arrhythmic events
26,27). In interpreting these results, it must be recognized that
ot all arrhythmias triggering appropriate ICD shocks for
T/VF would have resulted in sudden cardiac death and also
hat not all sudden cardiac deaths are a consequence of
entricular tachyarrhythmias. Because the true arrhythmogenic
ontribution of clinical characteristics can be better assessed by
igure 2. Kaplan-Meier curves for the probability of receiving approp
nterim hospitalization for coronary events (Post IH-CE) compared wit
how the curves for combined ventricular tachycardia (VT) and ventric
nd death, respectively.ppropriate ICD use (rather than overall survival), the current htudy restricted its primary evaluation to appropriate ICD
herapy and not mortality (although the latter was also evalu-
ted). Our results also point to the overall increase in mortality
n patients once they have been hospitalized for heart failure or
oronary events. It is also important to emphasize that the
ost important predictor of ICD therapy (IH-CHF) became
pparent only after the implant, during the follow-up period.
onclusions. The present study shows that among a com-
rehensive list of baseline clinical, echocardiographic, and
lectrophysiological variables (used in the MADIT-II
tudy), more symptomatic patients (NYHA functional class
II) with BUN 25 mg/dl, BMI 30 kg/m2, increased
igitalis use at baseline, and no beta-blocker use are at a
implantable cardioverter-defibrillator (ICD) therapy in patients after
period before any such hospitalization (Pre IH-CE). Panels A and B
brillation (VF) (with censoring at death), and for combined VT, VF,riate
h the
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ion, suggesting that worsening clinical condition, as re-
ected by an IH-CHF or IH-CE, is associated with a
ignificant increase in the risk for appropriate ICD therapy
nd death. This emphasizes the need for continued clinical
igilance during the follow-up period after ICD implanta-
ion to prevent heart failure exacerbations and coronary
vents, which, in turn, might decrease the risk of sudden
ardiac death and ICD therapy in this high-risk population.
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